Drugs / NNC0662-0419
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07525791 | Apr 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07101783 | Aug → Oct 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06737536 | Dec 2024 → Jul 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07639021 | Jun 2026 → Jun 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07415954 | Apr 2026 → Sep 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07184632 | Oct 2025 → Dec 2026 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0662-0419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07639021 ↗ |
| Route | Subcutaneous | “Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.” NCT06737536 ↗ |